Generics Safe Harbor Question Could Derail Biosimilars

By Rachel Slajda (August 21, 2012, 10:13 PM EDT) -- Biologic drug sponsors may have a powerful weapon to block competition from cheaper biosimilars, experts say, if they can successfully argue that the generic drug law's safe harbor from patent infringement expires the moment a drug wins regulatory approval....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!